LMR Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

LMR Partners’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-347,207	Closed	-$1.06M	–	1720
2024 Q4	$1.06M	Sell	347,207 -1,897,193	-85%	-$8.26M	0.01%	723
2024 Q3	$11.6M	Buy	+2,244,400	New	+$11.2M	0.09%	192
2022 Q4	–	Sell	-100,000	Closed	-$2.7M	–	1311
2022 Q3	$2.7M	Buy	+100,000	New	+$2.03M	0.05%	428

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

LMR Partners's RVNC Position: Q1 2025 in Review

LMR Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 347,207 shares — an estimated $1.06M sold.

LMR Partners first reported a position in RVNC in Q3 2022 and held it in 3 quarters. The position peaked at $11.6M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

LMR Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 347,207 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.06M.
LMR Partners first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 3 quarters.
LMR Partners's Revance Therapeutics, Inc. position peaked at $11.6M in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.